The detailed information for PTAB case with proceeding number IPR2017-01115 filed by Pfizer, Inc. against Genentech, Inc. et al. on Mar 24, 2017. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2017-01115
Filing Date
Mar 24, 2017
Petitioner
Pfizer, Inc.
Respondent
Genentech, Inc. et al.
Status
Terminated
Respondent Application Number
09564288
Respondent Tech Center
1600
Respondent Patent Number
7820161
Institution Decision Date
Jul 18, 2017
Termination Date
Jul 18, 2017

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

IPR2016-01614 Final Written Decision

Feb 22, 2018PAPERBOARD

Granting Motion for Pro Hac Vice Recognition of Mr. Charles B. Klein and Mr. Eimeric Reig-Plessis 37 C.F.R. sec 42.10(c)

Jul 18, 2017PAPERBOARD

Decision Institution of Inter Partes Review, Grant of Motion for Joinder, and Grant of Joint Motion to Dismiss Certain Challenges in the Petition

Jul 18, 2017PAPERBOARD

Joint Motion to Dismiss

Jul 10, 2017PAPERPATENT OWNER

Ex. 1058 - Declaration of Charles B. Klein ISO PHV Motion

May 9, 2017EXHIBITPETITIONER

Petitioner's Unopposed Motion For Pro Hac Vice Admission Of Charles B. Klein And Eimeric Reig-Plessis

May 9, 2017PAPERPETITIONER

Ex. 1059 - Declaration of Eimeric Reig-Plessis ISO PHV Motion

May 9, 2017EXHIBITPETITIONER

Petitioner's Updated Exhibit List (05 09 2017)

May 9, 2017PAPERPETITIONER

Notice of Deposition of Elena Massarotti

May 5, 2017PAPERPATENT OWNER

Power of Attorney

Apr 14, 2017PAPERPATENT OWNER

Mandatory Notice

Apr 14, 2017PAPERPATENT OWNER

Notice of Accepting Corrected Petition

Apr 11, 2017PAPERBOARD

Klareskog, Double-Blind Randomised Controlled Trial

Apr 7, 2017EXHIBITPETITIONER

Notice of Defective Petition

Apr 6, 2017PAPERBOARD

U.S. Patent 7,820,161

Mar 24, 2017EXHIBITPETITIONER

Declaration of Elena Massarotti MD

Mar 24, 2017EXHIBITPETITIONER

Elena Massarotti CV

Mar 24, 2017EXHIBITPETITIONER

Second Declaration of Ronald F. van Vollenhoven, dated January 19, 2010

Mar 24, 2017EXHIBITPETITIONER

William Schwieterman FDA Conversation

Mar 24, 2017EXHIBITPETITIONER

Eisenberg letter to Genetech Oncology & IDEC

Mar 24, 2017EXHIBITPETITIONER

Gryn letter to Parker, dated May 6, 1998

Mar 24, 2017EXHIBITPETITIONER

Saleh letter to Comprehensive Cancer Center, dated October 1, 1998

Mar 24, 2017EXHIBITPETITIONER

Latov letter to Horvath, dated November 16, 1998

Mar 24, 2017EXHIBITPETITIONER

Pestronk letter to Department of Neurology, dated October 12, 1998

Mar 24, 2017EXHIBITPETITIONER

Looney letter to Duthcer dated January 15, 1999

Mar 24, 2017EXHIBITPETITIONER

American Colelge of Rheumatology Subcommittee

Mar 24, 2017EXHIBITPETITIONER

T. Pincus & C.M. Stein, No Evidence of disease in rheumatoid arthritis

Mar 24, 2017EXHIBITPETITIONER

Kremer, Methotrexate for Rheumatoid Arthritis

Mar 24, 2017EXHIBITPETITIONER

ODell, Methotrexate Use (1997)

Mar 24, 2017EXHIBITPETITIONER

Boers, World Health Organization

Mar 24, 2017EXHIBITPETITIONER

Boers et al., The Lancet, 350.309-18 (1997)

Mar 24, 2017EXHIBITPETITIONER

Felson American College of Rheumatology

Mar 24, 2017EXHIBITPETITIONER

Kremer, Combination Therapy with Biologic Agents in Rheumatoid Arthritis

Mar 24, 2017EXHIBITPETITIONER

Guidance for Industry Clinical Development Programs for Drugs

Mar 24, 2017EXHIBITPETITIONER

Weinblatt et al., New England Journal of Medicine

Mar 24, 2017EXHIBITPETITIONER

Maini et al., Arthritis & Rheumatism

Mar 24, 2017EXHIBITPETITIONER

First Declaration of Ronald F. van Vollenhoven, dated July 30, 2007

Mar 24, 2017EXHIBITPETITIONER

IPR2015-00415 Patent Owner's Preliminary Response

Mar 24, 2017EXHIBITPETITIONER

Maloney Phase 1 Clinical Trial Using Escalating Single-Dose Infusion (1994)

Mar 24, 2017EXHIBITPETITIONER

Maloney IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy (1997)

Mar 24, 2017EXHIBITPETITIONER

WO 95.03770

Mar 24, 2017EXHIBITPETITIONER

Maloney et al., IDEC-C2B8 (1997)

Mar 24, 2017EXHIBITPETITIONER

Edwards, The Predictable Effect of Small Immune Complexes

Mar 24, 2017EXHIBITPETITIONER

Edwards, The case for Killing Cells with ANTI-CD20 in RA

Mar 24, 2017EXHIBITPETITIONER

The University College London Hospitals, October 30, 1998 Letter

Mar 24, 2017EXHIBITPETITIONER

Moreland Etanercept Therapy in Rheumatoid Arthritis

Mar 24, 2017EXHIBITPETITIONER

Remicade Label 1998

Mar 24, 2017EXHIBITPETITIONER

Wendler, Rituximab in Practice

Mar 24, 2017EXHIBITPETITIONER

Edwards, Efficacy of B-Cell-Targeted Therapy (2004)

Mar 24, 2017EXHIBITPETITIONER

EXPUNGED

Mar 24, 2017EXHIBITPETITIONER

Bathon, Comparison of Etanercept and Methotrexate (2000)

Mar 24, 2017EXHIBITPETITIONER

Gabriel, the Epidemiology of Rheumatoid Arthritis

Mar 24, 2017EXHIBITPETITIONER

The Joint UCL,UCLH Committees on the Ethics of Human Research

Mar 24, 2017EXHIBITPETITIONER

Letter from the Medicines Control Agency to Edwards

Mar 24, 2017EXHIBITPETITIONER

Information for patients undergoing treatment of rheumatoid arthritis

Mar 24, 2017EXHIBITPETITIONER

Rituxan label 1997

Mar 24, 2017EXHIBITPETITIONER

Kremer (1995)

Mar 24, 2017EXHIBITPETITIONER

Declaration by Jonathan Charles Wright Edwards

Mar 24, 2017EXHIBITPETITIONER

FDA, 64 Fed. Reg. 7898

Mar 24, 2017EXHIBITPETITIONER

Buch, Updated consensus statemetn on the use of rituximab

Mar 24, 2017EXHIBITPETITIONER

Decision of the European Patent Office re-EP1179681

Mar 24, 2017EXHIBITPETITIONER

FDA, Rituxan Approval Letter, 97-0244 (November 26, 1997)

Mar 24, 2017EXHIBITPETITIONER

1997 Form 10-K405.A filed by IDEC Pharmaceuticals

Mar 24, 2017EXHIBITPETITIONER

Declaration from Internet Archive

Mar 24, 2017EXHIBITPETITIONER

ODell, Treatment of Rheumatoid Arthritis with Methotrexate Alone

Mar 24, 2017EXHIBITPETITIONER

Kalden, Rescue of DMARD Failure by Means of Monoclonal Antibodies

Mar 24, 2017EXHIBITPETITIONER

Drugs@FDA, FDA Applciation No. (BLA) 103705

Mar 24, 2017EXHIBITPETITIONER

Internet Archive Capture of Genentech Website for Rituxan

Mar 24, 2017EXHIBITPETITIONER

Pfizer, Inc.s Power of Attorney

Mar 24, 2017PAPERPETITIONER

MOTION FOR JOINDER

Mar 24, 2017PAPERPETITIONER

PETITION FOR INTER PARTES REVIEW

Mar 24, 2017PAPERPETITIONER